Last Update

2015-02-27T00:00:00.000Z

This profile was last updated on .

Is this you? Claim your profile.

Wrong Arthur Sands?

Dr. Arthur T. Sands Ph.D.

Chief Executive Officer

Nurix , Inc.

Direct Phone: (415) ***-****       

Get ZoomInfo Grow

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Nurix , Inc.

1700 Owens Street, Suite 290

San Francisco, California 94158

United States

Company Description

Nurix, Inc. is a leader in the discovery of small molecules that modulate the ubiquitin proteasome system (UPS) to address significant, unmet medical needs. The UPS is a regulatory pathway that controls protein levels, a function vital to the healthy life ... more

Find other employees at this company (35)

Background Information

Employment History

Chief Executive Officer and Board Director

Nurix , Inc.

President and Chief Executive Officer

Lexicon Pharmaceuticals Inc

Affiliations

Board Member
Nurix , Inc.

Founder
Lexicon Pharmaceuticals Inc

Education

B.A.

economics and political science

Yale University

Ph.D

Ph.D.

Baylor College of Medicine

M.D.

Baylor College of Medicine

Web References (153 Total References)


Nurix | Board Of Directors

www.nurix-inc.com [cached]

Arthur T. Sands, M.D., Ph.D. Chief Executive Officer and Board Director

Arthur T. Sands, M.D., Ph.D., serves as the Chief Executive Officer at Nurix and is a member of the company's board of directors. Prior to joining Nurix, Dr. Sands co-founded Lexicon Pharmaceuticals and served as President, Chief Executive Officer and a Director since 1995. At Lexicon, Dr. Sands pioneered the development of large-scale gene knockout technology for use in drug discovery and guided the evolution of Lexicon from a research-stage company to a drug development company, catalyzed by numerous alliances with Bristol Myers Squibb, Takeda and Genentech, and generating more than $450 million in revenue. Dr. Sands serves as Adjunct Professor in the Department of Human and Molecular Genetics at Baylor College of Medicine. He has also published many scientific and medical articles and is an inventor on numerous patents related to the discovery of human genes and their use in the development of new therapies. Dr. Sands holds an M.D. and a Ph.D. from Baylor College of Medicine and a B.A. in economics and political science from Yale University.


Board of Directors - BioHouston

www.biohouston.org [cached]

Arthur T. Sands M.D., Ph.D., CEO, Nurix, Inc.


Nurix Names Arthur T. ...

www.fiercebiotech.com [cached]

Nurix Names Arthur T. Sands, M.D., Ph.D., Chief Executive Officer Share Tools Print

Nurix Names Arthur T. Sands, M.D., Ph.D., Chief Executive Officer
SAN FRANCISCO, Calif. - September 18, 2014 - Nurix, Inc., a leader in discovering and developing therapies that modulate the ubiquitin proteasome system (UPS), announced today the appointment of Arthur T. Sands, M.D., Ph.D., as chief executive officer. Dr. Sands succeeds interim chief executive officer Mark A. Goldsmith, M.D., Ph.D., a partner at Third Rock Ventures, who will continue service to the company as chairman of its board of directors.
...
"I am delighted to join Nurix at this point in the company's evolution as it establishes a broadly applicable platform in drug discovery based on its innovative research on the selective modulation of ubiquitin ligases for breakthrough applications in cancer and other diseases," said Dr. Sands. "Nurix has already built a strong foundation with world-renowned founders, collaborators and an outstanding scientific team. I would like to thank Mark for his leadership since the inception of the Company, and look forward to working with him, Nurix's board of directors and its growing team on behalf of patients with life-threatening diseases."
Prior to joining Nurix, Dr. Sands co-founded Lexicon Pharmaceuticals (Nasdaq: LXRX) and served as president, chief executive officer and a director since 1995. At Lexicon, Dr. Sands pioneered the development of large-scale gene knockout technology for use in drug discovery and guided the evolution of Lexicon from a research-stage company to a drug development company, catalyzed by numerous alliances with Bristol Myers Squibb, Takeda and Genentech, and generating more than $450 million in revenue. Lexicon's independently developed product portfolio, now approaching late stage development and commercialization, includes small molecules directed to novel targets for treatment of carcinoid syndrome, type 1 diabetes and type 2 diabetes. Dr. Sands serves as adjunct professor in the Department of Human and Molecular Genetics at Baylor College of Medicine. He has also published many scientific and medical articles and is an inventor on numerous patents related to the discovery of human genes and their use in the development of new therapies. Dr. Sands holds an M.D. and a Ph.D. from Baylor College of Medicine and a B.A. in economics and political science from Yale University.


>Nurix has named Dr. Arthur ...

www.fiercebiotech.com [cached]

>Nurix has named Dr. Arthur Sands as chief executive officer. Release


Management Team | About Us

www.lexicon-genetics.com [cached]

Arthur T. Sands, M.D., Ph.D., President and Chief Executive Officer

...
Arthur Sands
Dr. Sands co-founded Lexicon and has been our president and chief executive officer and a director since September 1995. At Lexicon, Dr. Sands pioneered the development of large-scale gene knockout technology for use in drug discovery to bring innovative drugs to patients. He has overseen the evolution of Lexicon from a research-stage company to a drug development company, including implementing the strategy to integrate chemistry capabilities with Lexicon's powerful genetics platform to create a unique drug discovery engine. Dr. Sands was also instrumental in establishing Lexicon's major alliances with pharmaceutical companies as well as implementing the company's financing strategy.
...
Before founding Lexicon, Dr. Sands served as an American Cancer Society postdoctoral fellow in the Department of Human and Molecular Genetics at Baylor College of Medicine. He received his B.A. in economics and political science from Yale University and his M.D. and Ph.D. from Baylor College of Medicine where he studied gene knockout technology and tissue-specific gene regulation in transgenic mice.
...
With Dr. Sands, he has co-authored numerous scientific and drug development publications focusing on gene knockout technology and drug discovery.

Similar Profiles

Other People with this Name

Other people with the name Sands

Morgan Sands
Saint Mary's College Dance Marathon

Jonathan Sands
Paul Sawyier Public Library

Diana Sands
Boeing

Leonard Sands
Florida Association of Criminal Defense Lawyers Inc

Stan Sands
Georgia State Golf Association

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory